Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC)

References

• Monfardini S. Survival in chronic myelogenous leukemia: influence of treatment and extent of disease and diagnosis. Cancer 1973; 31: 492
   PubMed Web of Science ®Google Scholar
• Spiers A. S. D., Goldman J. M., Catovsky D. Multi-drug chemotherapy for acute leukemia. Cancer 1977; 40: 20
   PubMed Web of Science ®Google Scholar
• Karanas A., Silver R. J. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 1968; 32: 445
   PubMed Web of Science ®Google Scholar
• Peterson L. C. Blast crisis as an initial or terminal manifestation of chronic myeloid leukemia: a study of 28 patients. Am J Med 1976; 60: 209
   PubMed Web of Science ®Google Scholar
• Boggs D. R. The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia. Semin Oncol 1976; 2: 289
   Google Scholar
• Boggs D. R. Hematopoietic stem cell theory in relation to possible lymphoblastic conversion of chronic myeloid leukemia. Blood 1974; 44: 449
   PubMed Web of Science ®Google Scholar
• Rosenthal S. Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. Am J Med 1977; 63: 542
   PubMed Web of Science ®Google Scholar
• Rosenthal S. Erythroblastic transformation of chronic granulocytic leukemia. Am J Med 1977; 63: 116
   PubMed Web of Science ®Google Scholar
• Breton-Gorius J. The blast crisis of chronic granulocytic leukemia: megakaryoblastic nature of cells as revealed by the presence of platelet peroxidase: a cytochemical ultra-structural study. Br J Haematol 1978; 39: 295
   PubMed Web of Science ®Google Scholar
• Canellos G. P., DeVita V. T., Whang-Peng J., Carbone P. Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood 1971; 38: 671
   PubMed Web of Science ®Google Scholar
• Jain K., Arlin Z., Mertelsmann R., Gee T., Kempin S., Koziner B., Middleton A., Jhanwar S., Chaganti R., Clarkson B. Philadelphia chromosome and terminal transferase-positive acute leukemia: simularity of terminal phase of chronic myelogenous leukemia and de novo acute presentation. J Clin Oncol 1983; 1: 669
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J. Blastic transformation of chronic myelocytic leukemia—clinical manifestations, prognostic factors, and results of therapy. Scand J Haematol 1977; 18: 292
   PubMedGoogle Scholar
• Coleman M., Silver R. T., Pajak T. F., Cavalli F., Rai K. R., Kostinas J. E., Glidewell O., Holland J. F. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: Cancer and Leukemia Group B studies. Blood 1980; 55: 29
   PubMed Web of Science ®Google Scholar
• Griffin J. D., Todd R. F., III, Ritz J., Nadler L. M., Canellos G. P., Rosenthal D., Gallivan M., Reveridge R. P., Weinstein H., Karp D., Schlossman S. F. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 1983; 61: 85
   PubMed Web of Science ®Google Scholar
• Arlin Z. A., Silver R., Cassileth P., Armentrout S., Gams R., D'Aghestani A., Coleman M., Schoch I., Dukart G. Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 1985; 69: 61
   PubMedGoogle Scholar
• Bakowski M. T., Brearley R. L., Wrigley P. F. M. Treatment of blast crisis of chronic myeloid leukemia with ICRF-159 (Razoxane). Cancer Treat Rep 1979; 63: 2085
   PubMedGoogle Scholar
• Arlin Z. A., Sklaroff R. B., Gee T. S. Phase I and II trial of 4′-(9-Acridinylamino) methane sulfur-in-anisidine in patients with acute leukemia. Cancer Res 1980; 40: 3304
   PubMed Web of Science ®Google Scholar
• Berman E., Raymond V., Gee T. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Sem Oncol 1989; 16: 30
   PubMed Web of Science ®Google Scholar
• Schiffer C. A., De Bellis R., Kasdorf H. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Cancer Treat Rep 1982; 66: 267
   PubMedGoogle Scholar
• Herzig R. H., Wolff S. N., Lazarus H. M., Phillips G. L., Karanes C., Herzig G. P. High dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361
   PubMed Web of Science ®Google Scholar
• Lacoboni S. J., Plunkett W., Kantarjian H. M. High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986; 4: 1079
   PubMed Web of Science ®Google Scholar
• Spiers A. S. D. Metamorphosis of chronic granulocytic leukaemia: Diagnosis classification and management. Br J Haematol 1979; 41: 1
   PubMed Web of Science ®Google Scholar
• Goto T., Nishikori M., Arlin Z., Gee T., Kempin S., Burchenal J., Strife A., Wisniewski D., Lambek C., Little C., Jhanwar S., Chaganti R., Clarkson B. Growth characteristics of leukemic and normal hematopoietic cells in Ph1 + chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59: 793
   PubMed Web of Science ®Google Scholar
• Capizzi R. L., Griffin F., Cheng Y. C., Bailey K., Rudnick S. A. High dose Ara-c with asparaginase (A'ase) in the treatment of refractory leukemia. Proc Am Assoc Cancer Res 1980; 21: 148, (abstr)
   Web of Science ®Google Scholar
• Capizzi R. L., Poole M., Cooper M. R. Treatment of poor risk acute leukemia with sequential Ara-C and asparaginase. Blood 1983; 63: 694
   Web of Science ®Google Scholar
• Vallejos C. S., Trujillo J. M., Cork A., Bodey G. P., McCredie K. B., Freireich E. J. Blastic crisis in chronic granulocytic leukemia: Experience in 39 patients. Cancer 1974; 34: 1806
   PubMed Web of Science ®Google Scholar
• George C. B., Mansour R. P., Redmond J., Ill, Gandara D. R. Hepatic dysfunction and jaundice following high dose cytosine arabinoside. Cancer 1984; 54: 2360
   PubMed Web of Science ®Google Scholar
• Preisier H. D., Raza A., Higby D. Treatment of myeloid blastic crisis of chronic myelogenous leukemia. Cancer Treat Rep 1984; 68: 1351
   PubMedGoogle Scholar
• Rudnick S. A., Cadman E. C., Capizzi R. L., Skeel R. T., Bertino J. R., McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979; 44: 1189
   PubMed Web of Science ®Google Scholar
• Griffin J. D., Tantravahi R., Canellos G. P., Wisch J. S., Reinherz E. L., Sherwood G., Beveridge R. P., Daley J. F., Lane H., Schlossman S. F. T. cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood 1983; 61: 640
   PubMed Web of Science ®Google Scholar